arrow
H

Henry Pertinez

university of liverpool
H指数:20
被引数:1,548

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study

奥普米gia静脉注射给药在住院COVID-19患者中的最佳剂量与安全性:一项剂量递增、随机对照的Ib期研究

2026-03-180
OAAI
Accelerating Generic Long-Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

加速通用长效抗逆转录病毒药物用于全球艾滋病治疗:研讨会成果与获取路线图

2026-02-010
OAAI
Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial

HIRIF试验中药物基因组学对一线抗结核药物药代动力学的影响

2025-04-170
PRE
Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters
2024-11-270
OAAI
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
2024-08-060
OAAI
Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters
2023-11-233
OAAI
Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of Mycobacterium tuberculosis Infection
2022-11-301
OAAI
High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis
2022-03-234
OAAI
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
2021-11-1314
OAAI
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
2021-08-2783
OAAI